Dr. Patrick M. Moriarty, MD
Professor of Medicine at The University of Kansas Medical Center in Kansas City, Kansas. He has an extensive clinical background from his clinical trials, research, and peer review experience.
Professional Background
Patrick M. Moriarty, MD is a Professor of Medicine at The University of Kansas Medical Center in Kansas City, Kansas. He is the Director of Clinical Pharmacology and the Atherosclerosis & Lipoprotein-Apheresis Center. He earned his Doctorate at the University of Rome School of Medicine and Surgery, Italy and completed his residency in Internal Medicine and training in Clinical Pharmacology at the University of Kansas Medical Center, in Kansas City, Kansas.
Dr. Moriarty is a fellow of the American College of Physicians, the American College of Cardiology, the European Society of Cardiology, National Lipid Association and he was the 2014-2015 president of the International Society for Apheresis. He serves as a manuscript reviewer for multiple scientific journals and is the associate editor for the Journal of Clinical Apheresis and Clinical Lipidology.
Dr. Moriarty has published well over 150 peer-reviewed articles/chapters. His research activities include atherosclerosis, familial hypercholesterolemia, Lp(a), Lipoprotein-Apheresis, vascular Inflammation, dementia, and hemorheology. He has participated in numerous clinical trials related to dyslipidemia, Lp(a), obesity, hypertension, and diabetes. Dr. Moriarty serves on several Advisory Boards including the FH Foundation. His clinical activities involve the treatment and diagnosis of atherosclerosis and cardiovascular disease. The University of Kansas Lipoprotein-Apheresis Center is the largest in North America for treating Familial Hypercholesterolemia and elevated Lp(a).
Education and Training
BA, St. Michael's Col.
MD, Univ. di Roma
Licensure, Accreditations & Certifications
Patrick M. Moriarty, MD, Kansas State Board of Healing Arts
Research Overview
His clinical activities involve the treatment and diagnosis of atherosclerosis and cardiovascular disease. The University of Kansas Lipid-Apheresis Center is the largest in North America for the treatment of Familial Hypercholesterolemia and elevated Lp(a). Dr. Moriarty is a fellow of the American College of Physicians, the American College of Cardiology, the European Society of Cardiology, National Lipid Association and he was the 2014-2015 president of the International Society for Apheresis.His clinical background extends into his research efforts where he currently is the principal investigator on 10 clinical trials. Throughout his more than 20 year research tenure, Dr. Moriarty has served as Principal investigator on more than 100 trials, co-investigator on 6, and medical monitor on 2. He serves as a manuscript reviewer for multiple peer-reviewed journals and is the associate editor for the Journal of Clinical Apheresis and Clinical Lipidology.